Skip to main content

Hemolytic uremic syndrome caused by E. coli O157 infection

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

References

  1. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005;295:405–18.

    CAS  Article  Google Scholar 

  2. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988;171:45–50.

    CAS  Article  Google Scholar 

  3. Novicki TJ, Daly JA, Mottice SL, Carroll KC. Comparison of sorbitol MacConkey agar and a two-step method which utilizes enzyme-linked immunosorbent assay toxin testing and a chromogenic agar to detect and isolate enterohemorrhagic Escherichia coli. J Clin Microbiol. 2000;38:547–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Fratamico PM, Sackitey SK, Wiedmann M, Deng MY. Detection of Escherichia coli O157:H7 by multiplex PCR. J Clin Microbiol. 1995;33:2188–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Besser RE, Griffin PM. Escherichia coli o157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease. Annu Rev Med. 1999;50:355–67.

    CAS  Article  Google Scholar 

  6. Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res. 2001;50:163–71.

    CAS  Article  Google Scholar 

  7. Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology. 2012;217:195–203.

    CAS  Article  Google Scholar 

  8. Kumar V, Abbas A, Aster J. Robbins basic pathology. 9th ed. Philadelphia: Elsevier Saunders; 2013.

    Google Scholar 

  9. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic–uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930–6.

    CAS  Article  Google Scholar 

  10. Panos GZ, Betsi GI, Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther. 2006;24:731–42.

    CAS  Article  Google Scholar 

  11. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, et al. Eculizumab in severe Shiga-Toxin–Associated HUS. N Engl J Med. 2011;364:2561–3.

    CAS  Article  Google Scholar 

  12. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256–64.

    CAS  Article  Google Scholar 

  13. Schuller Y, Hollak CEM, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review. Orphanet J Rare Dis BioMed Central. 2015;10:92.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph A. Prahlow.

Ethics declarations

Conflict of interest

Authors PB, RB, and JP declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies/tests involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the parent(s) for all medical procedures described in this report, with the exception of the autopsy, which was performed under the jurisdiction of the medical examiner’s office. The informed consent included permission for specimen testing and record review for teaching and research purposes.

Support

No sources of financial support.

Disclaimers

None.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bystrom, P.V., Beck, R.J. & Prahlow, J.A. Hemolytic uremic syndrome caused by E. coli O157 infection. Forensic Sci Med Pathol 13, 240–244 (2017). https://doi.org/10.1007/s12024-017-9852-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12024-017-9852-y

Keywords

  • Hemolytic Uremic Syndrome (HUS)
  • Coli O157
  • Eculizumab
  • Shiga-like Toxin
  • Paroxysmal Nocturnal Hematuria